Orosomucoid is an independent predictor of prognosis in chronic heart failure

Related Experiment Video

Updated: Mar 18, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

750

Petra Kaplan1, Bojan Vrtovec2, Borut Jug2

  • 1, Ljubljana, Slovenia. petrakaplan@gmail.com.

Wiener Klinische Wochenschrift
|July 6, 2016
PubMed

Insights

Orosomucoid, an inflammation marker, predicts worse outcomes in heart failure patients. Higher levels indicate increased risk of heart failure deaths and hospitalizations, aiding prognosis.

Area of Science:

  • Cardiology
  • Clinical Biochemistry
  • Inflammation Research

Background:

  • Heart failure is characterized by low-grade inflammation.
  • Orosomucoid is a key marker of inflammation.

Purpose of the Study:

  • To evaluate the prognostic significance of orosomucoid in outpatients with heart failure.
  • To determine if orosomucoid levels predict adverse events in heart failure.

Main Methods:

  • Orosomucoid levels were measured at baseline in 134 chronic heart failure outpatients.
  • Patients were followed for heart failure-related deaths and hospitalizations.
  • Cox multivariate analysis was used to assess prognostic factors.

Main Results:

  • A total of 134 patients were included (median age 71, 36% LVEF).
  • Orosomucoid levels above the median (>497 mg/l) were an independent predictor of prognosis.
  • Elevated orosomucoid (HR=2.86) predicted events after adjusting for multiple clinical factors.

Conclusions:

  • Orosomucoid levels independently predict heart failure-related mortality.
  • Orosomucoid is a valuable prognostic marker for hospitalizations in chronic heart failure patients.
Abstract

Keywords:
BiomarkerHeart failureInflammationOrosomucoidRisk prediction

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
539
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
511
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
797
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
478
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K